Citation Impact
Citing Papers
Synthetic lethality between CCNE1 amplification and loss of BRCA1
2013
CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
2015
A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
2012
Nuclear Lamin-A Scales with Tissue Stiffness and Enhances Matrix-Directed Differentiation
2013 StandoutScience
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.
2003
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
2009
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas
2008
Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.
1998
Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen‐receptor status and predicts for poor prognosis
2003
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis
1996 Nature
Ordering S phase and M phase in the cell cycle
1994 StandoutNobel
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
2014
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
2011 Nature
A view on drug resistance in cancer
2019 StandoutNature
APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
2011
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
1995
THE LOCALIZATION OF p34cdc2 IN THE CELLS OF NORMAL, HYPERPLASTIC, AND MALIGNANT EPITHELIAL AND LYMPHOID TISSUES OF THE ORAL CAVITY
1996 StandoutNobel
MuSiC: Identifying mutational significance in cancer genomes
2012
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
2005 StandoutNature
Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
1997 Standout
Ovarian cancer
2014 Standout
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
2011
Tailoring to RB: tumour suppressor status and therapeutic response
2008
The language of covalent histone modifications
2000 StandoutNature
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells
2003
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
p65cdc18 Plays a major role controlling the initiation of DNA replication in fission yeast
1995 StandoutNobel
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
2009
The Epigenomics of Cancer
2007 Standout
Autocrine Signalling Through erbB Receptors Promotes Constitutive Activation of Protein Kinase B/Akt in Breast Cancer Cell Lines
2003
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Metagenomic biomarker discovery and explanation
2011 Standout
Identification of ‘Non‐Proliferating’ B16 Melanoma Cells Using Monoclonal Antibody (Ad203) Against the M1 Subunit of Ribonucleotide Reductase
1988
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
2016
An invasion-related complex of cortactin, paxillin and PKCμ associates with invadopodia at sites of extracellular matrix degradation
1999
Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer
2013
Histone acetylation: facts and questions
1994
More hippocampal neurons in adult mice living in an enriched environment
1997 StandoutNature
Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression
2001 StandoutNobel
The microenvironment of the tumour–host interface
2001 StandoutNature
Potent Prostaglandin A1 Analogs That Suppress Tumor Cell Growth through Induction of p21 and Reduction of Cyclin E
1998 StandoutNobel
Diet rapidly and reproducibly alters the human gut microbiome
2013 StandoutNature
Immunocytochemical detection of 5′-bromodeoxyuridine incorporation in the central nervous system of the mouse
1989
Specific protection against breast cancers by cyclin D1 ablation
2001 Nature
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
2010
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
The Oncogenic Activity of Cyclin E Is Not Confined to Cdk2 Activation Alone but Relies on Several Other, Distinct Functions of the Protein
2002
Cell cycle‐related variation and tissue‐restricted expression of human cyclin D1 protein
1994
Frequent Amplification of the Cyclin E Gene in Human Gastric Carcinomas
1995
Cancer immunotherapy comes of age
2011 StandoutNature
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas
1995
Cyclin D1 protein expression and function in human breast cancer
1994
Inhibition of the DNA‐binding activity of NF‐κB by gold compounds in vitro
1995
The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer
2011
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
1994 Standout
Creation of human tumour cells with defined genetic elements
1999 StandoutNature
Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer
1996
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
p27kip1: A Multifunctional Cyclin-Dependent Kinase Inhibitor with Prognostic Significance in Human Cancers
1999
Defects in the Ubiquitin Pathway Induce Caspase-independent Apoptosis Blocked by Bcl-2
1998 StandoutNobel
Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21
2015 StandoutNobel
Myosin-II inhibition and soft 2D matrix maximize multinucleation and cellular projections typical of platelet-producing megakaryocytes
2011
Inferring tumour purity and stromal and immune cell admixture from expression data
2013 Standout
Activation of cyclin A-dependent protein kinases during apoptosis.
1994
Metalle in der Medizin
1999
Inactivation of p16 in Human Mammary Epithelial Cells by CpG Island Methylation
1998
Cancer Cell Cycles
1996 StandoutScience
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
2012
Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice.
1994
Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero
1998 StandoutNobel
Generation and reproductive phenotypes of mice lacking estrogen receptor β
1998 StandoutNobel
Asymmetric Catalysis by Architectural and Functional Molecular Engineering: Practical Chemo- and Stereoselective Hydrogenation of Ketones
2001 StandoutNobel
Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases
2003 Standout
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
2016
The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human Cancer
1999
Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer
2015
The retinoblastoma protein and cell cycle control
1995 Standout
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
1994
Methods for Synchronizing Cells at Specific Stages of the Cell Cycle
1998
G 1 Events and Regulation of Cell Proliferation
1989 StandoutScience
Methylation of hypoxia-inducible factor (HIF)-1α by G9a/GLP inhibits HIF-1 transcriptional activity and cell migration
2018 StandoutNobel
Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery
2017 StandoutNobel
Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells
2013 StandoutScience
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
2002 StandoutNobel
A maize cDNA encoding a member of the retinoblastoma protein family: involvement in endoreduplication.
1996 StandoutNobel
A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling
2005 StandoutScience
APE1 is dispensable for S-region cleavage but required for its repair in class switch recombination
2014 StandoutNobel
Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase
1995 StandoutScience
THE UBIQUITIN SYSTEM
1998 StandoutNobel
Cyclin E, a Potential Prognostic Marker in Breast Cancer.
1997
Mechanisms and Genes of Cellular Suicide
1995 StandoutScience
Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E.
1996
Works of Anna DeFazio being referenced
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
2008
Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations
2013
Inhibition of DNA Binding and Transcriptional Activity of a Nuclear Receptor Transcription Factor by Aurothiomalate and Other Metal Ions
1991
Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines
2000
Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia
2001
Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival
2015
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
2010
Expression and tyrosine phosphorylation of EMS1 in human breast cancer cell lines
1996
High resolution melting for mutation scanning of TP53exons 5–8
2007
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
2012
Immunohistochemical detection of proliferating cells in vivo.
1987
Rapid fluorometric detection of drug resistant tumour cells
1985
Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines.
1992
Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.
1994
Expression and amplification of cyclin genes in human breast cancer.
1993
Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
1995
Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos.
1995